Stocks / NASDAQ / Immunomedics, Inc.

Immunomedics, Inc.

Our Opinion

Immunomedics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“In a preclinical study presented at the 2016 Annual Meeting of the American Society of Hematology, IMMU-140 was shown to have higher potency than naked IMMU-114 in acute lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML), and an added, if not 300 significant, survival benefit in experimental multiple myeloma (MM) and CLL. Importantly, it did not produce any undue toxicity in these four animal models of human blood cancers.” (Page 1) Read the following document

Company Description

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. [Source: MarketWatch]

Company Website: